Evidence map›Paper›PMID 26588476›Full record

ArticlePloS one2015

Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule.

Anthony A Portale, Martin Y H Zhang, Valentin David, Aline Martin, Yan Jiao, Weikuan Gu, Farzana Perwad

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Transcriptomics: a Solution for Renal Osteodystrophy?Current osteoporosis reports · 2020
    Review
  11. Osteocytic FGF23 and Its Kidney Function.Frontiers in endocrinology · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Anthony A PortaleDepartment of Pediatrics, Division of Nephrology, University of California San Francisco, San Francisco, California, United States of America.
Martin Y H ZhangDepartment of Pediatrics, Division of Nephrology, University of California San Francisco, San Francisco, California, United States of America.
Valentin DavidDepartment of Medicine, Division of Nephrology/Hypertension, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, United States of America.
Aline MartinDepartment of Medicine, Division of Nephrology/Hypertension, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, United States of America.
Yan JiaoDepartment of Orthopaedic Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.
Weikuan GuDepartment of Orthopaedic Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.
Farzana PerwadDepartment of Pediatrics, Division of Nephrology, University of California San Francisco, San Francisco, California, United States of America.
University of California, San Francisco · USNorthwestern University · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast growth factor 23 (FGF23) is a potent regulator of phosphate (Pi) and vitamin D homeostasis. The transcription factor, early growth response 1 (egr-1), is a biomarker for FGF23-induced activation of the ERK1/2 signaling pathway. We have shown that ERK1/2 signaling blockade suppresses renal egr-1 gene expression and prevents FGF23-induced hypophosphatemia and 1,25-dihydroxyvitamin D (1,25(OH)2D) suppression in mice. To test whether egr-1 itself mediates these renal actions of FGF23, we administered FGF23 to egr-1-/- and wild-type (WT) mice. In WT mice, FGF23 induced hypophosphatemia and suppressed expression of the renal Na/Pi cotransporters, Npt2a and Npt2c. In FGF23-treated egr-1-/- mice, hypophosphatemic response was greatly blunted and Na/Pi cotransporter expression was not suppressed. In contrast, FGF23 induced equivalent suppression of serum 1,25(OH)2D concentrations by suppressing renal cyp27b1 and stimulating cyp24a1 mRNA expression in both groups of mice. Thus, downstream of receptor binding and ERK1/2 signaling, we can distinguish the effector pathway that mediates FGF23-dependent inhibition of Pi transport from the pathway that mediates inhibition of 1,25(OH)2D synthesis in the kidney. Furthermore, we demonstrate that the hypophosphatemic effect of FGF23 is significantly blunted in Hyp/egr-1-/- mice; specifically, serum Pi concentrations and renal Npt2a and Npt2c mRNA expression are significantly higher in Hyp/egr-1-/- mice than in Hyp mice. We then characterized the egr-1 cistrome in the kidney using ChIP-sequencing and demonstrate recruitment of egr-1 to regulatory DNA elements in proximity to several genes involved in Pi transport. Thus, our data demonstrate that the effect of FGF23 on Pi homeostasis is mediated, at least in part, by activation of egr-1.

Indexed as

AnimalsEarly Growth Response Protein 1Fibroblast Growth Factor-23Fibroblast Growth FactorsGene Expression RegulationHypophosphatemiaKidney Tubules, ProximalMAP Kinase Signaling SystemMiceMice, TransgenicPhosphatesSodium-Phosphate Cotransporter Proteins, Type IIaSodium-Phosphate Cotransporter Proteins, Type IIcVitamin DEarly Growth Response Protein 1Egr1 protein, mouseFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsPhosphatesSlc34a1 protein, mouseSlc34a3 protein, mouseSodium-Phosphate Cotransporter Proteins, Type IIaSodium-Phosphate Cotransporter Proteins, Type IIcVitamin D

Identifiers

PMID26588476
PMCPMC4654537
OpenAlexW2180550475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.